AbelZeta's Novel Bispecific CAR-T Therapy Shows Promise for Refractory Autoimmune Diseases in First-in-Human Trial
核心洞察
AbelZeta Pharma (搜索) will present clinical data from the first-in-human Phase I trial of C-CAR168, an anti-CD20 (搜索)/BCMA (搜索) bispecific CAR-T therapy, at ACR Convergence 2025.
The therapy is designed to simultaneously target autoantibody-producing plasma cells and their B-cell precursors to achieve "immune reset" in refractory autoimmune diseases (搜索).
The abstract title indicates the therapy promotes immune reset and sustained drug-free remission in patients with treatment-resistant autoimmune conditions.
AbelZeta Pharma (搜索) announced that clinical data from its groundbreaking first-in-human Phase I trial of C-CAR168 will be presented at the American College of Rheumatology (ACR) Convergence 2025. The study represents a pioneering application of bispecific CAR-T cell therapy in refractory autoimmune diseases (搜索), marking a significant expansion of CAR-T technology beyond its traditional oncology applications.
Novel Dual-Target Approach
C-CAR168 is an autologous anti-CD20 (搜索)/BCMA (搜索) bispecific Chimeric Antigen Receptor T-cell therapy engineered to simultaneously target autoantibody-producing plasma cells and their B-cell precursors. This dual-targeting strategy aims to achieve what the company describes as an "immune reset" in patients with treatment-resistant autoimmune conditions.
The bispecific design addresses a critical therapeutic challenge in autoimmune diseases (搜索) by targeting both mature plasma cells responsible for pathogenic autoantibody production and the B-cell precursors that give rise to these problematic cells. This comprehensive approach could potentially provide more durable therapeutic responses compared to single-target strategies.
Clinical Trial Results
The Phase I trial (NCT06249438) enrolled patients with refractory autoimmune diseases (搜索) who had failed conventional treatments. According to the abstract title, the therapy "promotes immune reset and sustained drug free remission in refractory autoimmune diseases," suggesting encouraging efficacy signals in this challenging patient population.
The clinical data will be presented as a late-breaking poster at ACR Convergence 2025, scheduled for October 24-29, 2025, at McCormick Place in Chicago. The poster presentation is set for Tuesday, October 28, from 10:30 AM to 12:30 PM CT in Hall F1.
Expanding CAR-T Applications
This development represents a notable expansion of CAR-T cell therapy applications beyond hematological malignancies (搜索) and solid tumors (搜索) into inflammatory and immunological diseases. AbelZeta's approach leverages the precision and potency of CAR-T technology to address the underlying immune dysfunction in autoimmune conditions.
The company operates with centers of excellence in Rockville, Maryland, and Shanghai, China, conducting research and development in its own GMP facilities for early-stage clinical studies. AbelZeta's pipeline comprises multiple CAR-T therapies targeting various therapeutic areas, including hematological malignancies (搜索), solid tumors (搜索), and inflammatory diseases.
Clinical Significance
The potential for sustained drug-free remission in refractory autoimmune diseases (搜索) represents a significant therapeutic advance for patients who have exhausted conventional treatment options. Traditional immunosuppressive therapies often require long-term administration and carry risks of serious side effects, making the prospect of a one-time treatment that could provide durable remission particularly compelling.
The immune reset concept suggests that C-CAR168 may fundamentally reprogram the immune system's aberrant responses, potentially offering a curative rather than merely palliative approach to autoimmune disease management.